Rich66
12-13-2008, 08:27 PM
Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs
Programs include XL184, a Phase III inhibitor of MET, VEGFR2 and RET, and XL281, a Phase I Inhibitor of RAF Kinase
full article:
http://online.wsj.com/article/SB122904558621500589.html?mod=googlenews_wsj
Programs include XL184, a Phase III inhibitor of MET, VEGFR2 and RET, and XL281, a Phase I Inhibitor of RAF Kinase
full article:
http://online.wsj.com/article/SB122904558621500589.html?mod=googlenews_wsj